Navigation Links
Definitive diabetes indicator deceptively high in African-American children
Date:5/4/2010

New Orleans, LA Researchers at LSU Health Sciences Center New Orleans and Children's Hospital of New Orleans have found that there is a major difference in the hemoglobin A1c (HbA1c) response to blood glucose between African-American and Caucasian children with diabetes. HbA1c is the main test used to monitor diabetes and guide treatment decisions. African-American children test significantly higher than Caucasians who have similar average blood glucose levels. The research may explain why African Americans are at increased risk of diabetes complications. The study is published in the May 2010 issue of the journal, Diabetes Care.

The study has important implications for clinical practice. "The HbA1c can be deceptive in African American children with diabetes, misleading their doctors into believing that glucose levels are higher than they really are, " notes Stuart A. Chalew, MD, Professor of Pediatrics and Head of the Division of Endocrinology in the Department of Pediatrics at LSU Health Sciences Center New Orleans School of Medicine. "If doctors don't take both HbA1c and self-monitored blood sugar levels into account, they are likely to unintentionally provoke increased episodes of life-threatening hypoglycemia in African-American patients."

The research team, which also included James M. Hempe, PhD, Associate Professor of Pediatrics, and Jodi L. Kamps, PhD, Clinical Assistant of Pediatrics at LSU Health Sciences Center New Orleans, followed 276 children at Children's Hospital of New Orleans with type 1 diabetes over a six-year period. The average age of participants was 12.5 years with an average duration of diabetes of nearly 5 years. The researchers obtained HbA1c levels and mean blood glucose levels the average of self-monitored blood glucose measurements downloaded from strip-based glucose meters for periods of at least 30 days. By analyzing a hemoglobin glycation index (HGI) which assesses biological variation in A1c after accounting for the effect of mean blood glucose, the team found that there were significant differences in HGI groups by race but not by gender. About 58% of the African-American children were in the high HGI group compared to only about 24% of the Caucasian participants.

"Besides the risk of over-treating with insulin and provoking hypoglycemia, the data also suggest that there is a need for alternate therapies to reduce diabetes complications other than insulin and other glucose lowering agents," concludes Dr. Chalew.

According to the American Diabetes Association, almost 24 million people, or about 8% of the population of the United States, have diabetes, including about one in every 400-600 children and adolescents. It is the seventh leading cause of death and is the leading cause of kidney failure. Diabetes is associated with an increased risk of heart disease, stroke, high blood pressure, blindness, nervous system damage, and non-traumatic lower-limb amputations.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. Savor: Mindful Eating, Mindful Life -- The Definitive Guide to Changing the Way People Eat and Live
2. MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin
3. Definitive study confirms chemo benefit in postmenopausal breast cancer
4. Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions
5. Older women with diabetes face higher risk for colon cancer
6. Injection Helps Treat Hard-to-Control Type 2 Diabetes
7. People with diabetes are at higher risk of atrial fibrillation
8. Wounded Soldier Spared Diabetes With Emergency Transplant
9. BestofNorthCarolina.com Presents Their Inaugural 'Carolina Beach Bash' to Benefit the Juvenile Diabetes Research Foundation
10. Artificial Pancreas for Type 1 Diabetes Moves Closer to Reality
11. Hormones Tied to Diabetes Might Also Influence Fertility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... (PRWEB) , ... May 26, 2017 , ... A May ... who visit a doctor for colds or respiratory issues that are not responsive to ... time pressure on doctors may be largely responsible for the problem both in Canada ...
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... to review more than eighty-nine grant submissions all vying for nearly $1,000,000 in ... the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Amir Qureshi, ... System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System ... “We are pleased to be the first in Arkansas to introduce the most powerful ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
Breaking Medicine Technology: